Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 63,126
  • Shares Outstanding, K 15,712
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,392 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.00 +0.44%
on 02/14/20
4.75 -15.42%
on 02/04/20
-0.35 (-8.06%)
since 01/14/20
3-Month
3.65 +10.07%
on 12/10/19
5.69 -29.39%
on 11/19/19
-0.22 (-5.24%)
since 11/14/19

Most Recent Stories

More News
Pediatric Brain Tumor Drug Market is Growing Continuously and Could Reach US$1,659.4 Million by 2023

Pediatric brain tumors are abnormal growths that arise in the brain during childhood. Although brain tumors are rare overall, they are the most common solid tumor among children. What's important to remember...

CNSP : 4.02 (-1.29%)
WBIO.CN : 1.380 (+2.22%)
ABBV : 94.05 (-1.36%)
AZN : 47.85 (-3.00%)
PFE : 36.51 (-1.14%)
INO : 4.15 (+7.51%)
CNS Pharmaceuticals Announces Collaboration with European Partner to Expand Clinical Trials to Pediatric Brain Tumors

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced its plan to initiate a Phase...

CNSP : 4.02 (-1.29%)
WBIO.CN : 1.380 (+2.22%)
CNS Pharmaceuticals Announces Completion of GMP Manufacturing

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has completed the final...

RETA : 225.65 (-1.90%)
CNSP : 4.02 (-1.29%)
Global Glioblastoma Multiforme Drugs Market Projected Could Reach $1.4 Billion By 2025

Brain and other nervous system cancers are the 10th leading cause of death for men and women. The global Glioblastoma multiforme (GBM) drugs market to reach nearly $1.4 billion by 2025, expanding at a...

CNSP : 4.02 (-1.29%)
BCRX : 2.80 (-1.41%)
CLVS : 9.44 (-2.78%)
ACHN : 6.76 (+10.28%)
MGEN : 0.70 (-6.65%)
CNS Pharmaceuticals Completes Pilot Manufacturing Steps Pursuant to FDA Pre-IND Guidance

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced that Anthem Biosciences...

CNSP : 4.02 (-1.29%)
Global Brain Tumor Drugs Market Expected to Exceed $3 Billion Through 2022

Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity....

CNSP : 4.02 (-1.29%)
ADAP : 4.02 (+1.26%)
DARE : 1.28 (+3.23%)
VRNA : 7.28 (+4.18%)
PFE : 36.51 (-1.14%)
AXSM : 90.47 (+2.03%)
Growing Demand for Novel Drug Delivery Technologies that Allow Medication to Cross the Blood Brain Barrier

Reports say that the global drug delivery across brain barrier market size is expected to reach USD $4.6 billion by 2026, according to a new report by Grand View Research, Inc. registering a CAGR of 30.2%...

CNSP : 4.02 (-1.29%)
SRNE : 2.72 (-3.55%)
RARE : 61.13 (-2.81%)
VBIV : 1.53 (-3.77%)
PHAS : 4.76 (-6.30%)
Drug Delivery Across Blood Brain Barrier Market Worth $4.6 Billion by 2026

The success rate for cancer therapies has been limited due to a combination of factors, such as the treatment/drug's lack of penetration through the blood brain barrier. Reports say that the global drug...

CNSP : 4.02 (-1.29%)
AMRX : 4.91 (-1.41%)
MIRM : 16.90 (-0.94%)
AXSM : 90.47 (+2.03%)
HRTX : 21.00 (-2.37%)
Why Pharmaceutical R&D Global Spending Could Exceed $200 Billion by 2024

According to various industry and market publications, pharmaceutical companies spend, on average, 17% of revenues on R&D, making it one of the biggest spenders in this area. Outside of the semiconductor...

CNSP : 4.02 (-1.29%)
AGIO : 51.51 (-0.96%)
PTI : 1.71 (+3.64%)
LLY : 141.12 (-0.48%)
SGMO : 7.57 (unch)
Biotech Advancements in the Immuno-Oncology Field for Pediatric and Adult Brain Tumors

For the last half century, if not more, doctors have been working to learn more about brain tumors, ways to prevent them, how to best treat them, and how to provide the best care to people diagnosed with...

CNSP : 4.02 (-1.29%)
NLTX : 11.06 (-8.14%)
CDMO : 6.80 (unch)
AUPH : 18.71 (-1.78%)
ABEO : 3.17 (+2.59%)
Trade CNSP with:

Business Summary

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is...

See More

Key Turning Points

2nd Resistance Point 4.23
1st Resistance Point 4.12
Last Price 4.02
1st Support Level 3.96
2nd Support Level 3.90

See More

52-Week High 5.69
Fibonacci 61.8% 4.91
Fibonacci 50% 4.67
Fibonacci 38.2% 4.43
Last Price 4.02
52-Week Low 3.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar